In addition to the STEP trials, real-world studies and independent reviews further support the effectiveness of a variety of GLP-1 receptor agonists for weight management, with weight loss typically ranging from 5% to 15% depending on dose, duration, and adherence.28,29 A retrospective, noninterventional drug utilization cohort study in the United Kingdom evaluated the use of different varieties of liraglutide for weight management purposes.30 Among 604 individuals using Saxenda (liraglutide 3 g) and 4,853 individuals using Victoza (liraglutide 1.2 mg/1.8 mg), most were able to achieve 5% weight loss within 24 weeks.30 Emerging data on tirzepatide has also shown even greater weight reductions (up to 21% over 72 weeks) over other GLP-1s, as well as improved quality of life.31,32 Together, these findings show the support GLP-1s can provide in long-term weight management
Not evaluated by Health Canada or the FDA for therapeutic use.
It is worth noting the relatively small role that personalized semaglutide would play in its 2025 revenue projections
Most studies evaluated oral supplements, not patches, and even the oral supplements showed questionable results, making it extremely unlikely that patches would have any meaningful effects on weight loss in humans
GLP-1 receptor agonists are medications that imitate the effects of glucagon-like peptide-1, a hormone released after eating
Coenzyme Q concentration and total antioxidant capacity of human milk at different stages of lactation